A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The treatment of acute myeloid leukemia of older, medically non-fit patients still poses a highly unmet clinical need, and only few large, prospective studies have been performed in this setting. Given the established activity of hypomethylating agents such as 5-aza-2'-deoxycytidine (decitabine) in myelodysplastic syndromes and acute myeloid leukemia with 20-30% bone marrow blasts, we investigated whether this drug is also active in patients with more than 30% blasts. DESIGN AND METHODS: To evaluate the efficacy and toxicity of decitabine in patients over 60 years old with untreated acute myeloid leukemia ineligible for induction chemotherapy, 227 patients (median age, 72 years), many with comorbidities, adverse cytogenetics and/or preceding myelodysplastic syndrome were treated with this hypomethylating agent. During the initial decitabine treatment (135 mg/m(2) total dose infused intravenously over 72 hours every 6 weeks), a median of two cycles was administered (range, 1-4). All-trans retinoic acid was administered to 100 patients during course 2. Fifty-two patients who completed four cycles of treatment subsequently received a median of five maintenance courses (range, 1-19) with a lower dose of decitabine (20 mg/m(2)) infused over 1 hour on 3 consecutive days every 4-6 weeks. RESULTS: The complete and partial remission rate was 26%, 95% CI (20%, 32%), and an antileukemic effect was noted in 26% of patients. Response rates did not differ between patients with or without adverse cytogenetics; patients with monosomal karyotypes also responded. The median overall survival from the start of decitabine treatment was 5.5 months (range, 0-57.5+) and the 1-year survival rate was 28%, 95%CI (22%,34%). Toxicities were predominantly hematologic. CONCLUSIONS: Decitabine is well tolerated by older, medically non-fit patients with acute myeloid leukemia; myelosuppression is the major toxicity. The response rate and overall survival were not adversely influenced by poor-risk cytogenetics or myelodysplastic syndrome. Because of these encouraging results, randomized studies evaluating single-agent decitabine versus conventional treatment are warranted. The study is registered with the German Clinical Trials Registry, number DRKS00000069.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005) · Blood · doi:10.1182/blood-2005-05-2004 · Cited by 2,969
Cellular differentiation, cytidine analogs and DNA methylation
Jones, P. A., & Taylor, S. M. (1980) · Cell · doi:10.1016/0092-8674(80)90237-8 · Cited by 1,831 · cited 2×
“Presence of translocation (8;21) or inversion 16 was not an”
BackgroundMutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Self-citationEstey, E., & Döhner, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69780-8 · Cited by 1,296
Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Self-citationKantarjian, H., Oki, Y., Garcia-Manero, G., Huang, X., O'Brien, S., Cortes, J., Faderl, S., Bueso-Ramos, C., Ravandi, F., Estrov, Z., et al. (2007) · Blood · doi:10.1182/blood-2006-05-021162 · Cited by 685 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Burnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K. (2007) · Cancer · doi:10.1002/cncr.22496 · Cited by 619
Breems, D. A., Van Putten, W. L. J., De Greef, G. E., Van Zelderen-Bhola, S. L., Gerssen-Schoorl, K. B. J., Mellink, C. H. M., Nieuwint, A., Jotterand, M., Hagemeijer, A., Beverloo, H. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0259 · Cited by 580 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Self-citationWijermans, P., Lübbert, M., Verhoef, G., Bosly, A., Ravoet, C., Andre, M., & Ferrant, A. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.956 · Cited by 567 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Self-citationLübbert, M., Suciu, S., Baila, L., Rüter, B. H., Platzbecker, U., Giagounidis, A., Selleslag, D., Labar, B., Germing, U., Salih, H. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.9245 · Cited by 552
Self-citationDaskalakis, M., Nguyen, T. T., Nguyen, C., Guldberg, P., Köhler, G., Wijermans, P., Jones, P. A., & Lübbert, M. (2002) · Blood · doi:10.1182/blood.v100.8.2957 · Cited by 514 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Self-citationGarcia-Manero, G., Kantarjian, H. M., Sanchez-Gonzalez, B., Yang, H., Rosner, G., Verstovsek, S., Rytting, M., Wierda, W. G., Ravandi, F., Koller, C., et al. (2006) · Blood · doi:10.1182/blood-2006-03-009142 · Cited by 467 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Cashen, A. F., Schiller, G. J., O'Donnell, M. R., & DiPersio, J. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9178 · Cited by 464 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Soriano, A. O., Yang, H., Faderl, S., Estrov, Z., Giles, F., Ravandi, F., Cortes, J., Wierda, W. G., Ouzounian, S., Quezada, A., et al. (2007) · Blood · doi:10.1182/blood-2007-03-078576 · Cited by 390 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Büchner, T., Berdel, W. E., Haferlach, C., Haferlach, T., Schnittger, S., Müller-Tidow, C., Braess, J., Spiekermann, K., Kienast, J., Staib, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4245 · Cited by 338 · cited 1×
“8) duration of MDS; months, median (range) 8 (1-101) missing 14”
Sorror, M. L., Maris, M. B., Storb, R. F., Baron, F., Sandmaier, B. M., Maloney, D. G., & Barry, S. E. (2005) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2004.12.067 · Cited by 323 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Flotho, C., Claus, R., Batz, C., Schneider, M., Sandrock, I., Ihde, S., Plass, C., Niemeyer, C. M., & Lübbert, M. (2009) · Leukemia · doi:10.1038/leu.2008.397 · Cited by 315
Self-citationPhase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia
Blum, W., Klisovic, R. B., Hackanson, B., Liu, Z., Liu, S., Devine, H., Vukosavljevic, T., Huynh, L., Lozanski, G., Kefauver, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4169 · Cited by 315 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Self-citationFröhling, S., Schlenk, R. F., Kayser, S., Morhardt, M., Benner, A., Döhner, K., Döhner, H., & for the German-Austrian AML Study Group (2006) · Blood · doi:10.1182/blood-2006-04-014324 · Cited by 300 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Self-citationFandy, T. E., Herman, J. G., Kerns, P., Jiemjit, A., Sugar, E. A., Choi, S.-H., Yang, A. S., Aucott, T., Dauses, T., Odchimar-Reissig, R., et al. (2009) · Blood · doi:10.1182/blood-2009-02-203547 · Cited by 282 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Wheatley, K., Brookes, C. L., Howman, A. J., Goldstone, A. H., Milligan, D. W., Prentice, A. G., Moorman, A. V., Burnett, A. K., & on behalf of the United Kingdom National Cancer Research Institute Haematological Oncology Clinical Studies Group and Acute Myeloid Leukaemia Subgroup (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07663.x · Cited by 236
Evolution of decitabine development: Accomplishments, ongoing investigations, and future strategies
Jabbour, E., Issa, J., Garcia‐Manero, G., & Kantarjian, H. (2008) · Cancer · doi:10.1002/cncr.23463 · Cited by 224
Lubbert, M., Wijermans, P., Kunzmann, R., Verhoef, G., Bosly, A., Ravoet, C., Andre, M., & Ferrant, A. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02933.x · Cited by 224
Self-citationSchlenk, R. F., Dohner, K., Kneba, M., Gotze, K., Hartmann, F., del Valle, F., Kirchen, H., Koller, E., Fischer, J. T., Bullinger, L., et al. (2009) · Haematologica · doi:10.3324/haematol.13378 · Cited by 210
Medeiros, B. C., Othus, M., Fang, M., Roulston, D., & Appelbaum, F. R. (2010) · Blood · doi:10.1182/blood-2010-02-270330 · Cited by 209 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Deschler-Baier, B., de Witte, T., Mertelsmann, R. H., & Lübbert, M. (2006) · PubMed · Cited by 159
Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines
Qin, T., Youssef, E. M., Jelínek, J., Chen, R., Yang, A. S., Garcia‐Manero, G., & Issa, J. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2762 · Cited by 147 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Burnett, A. K., Russell, N. H., Kell, J., Dennis, M. W., Milligan, D. W., Paolini, S., Yin, J., Culligan, D. J., Johnston, P., Murphy, J. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4242 · Cited by 147
Malfuson, J. V., Etienne, A., Turlure, P., de Revel, T., Thomas, X., Contentin, N., Terré, C., Rigaudeau, S., Bordessoule, D., Vey, N., et al. (2008) · Haematologica · doi:10.3324/haematol.13309 · Cited by 138 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Cimino, G., Lo-Coco, F., Fenu, S., Travaglini, L., Finolezzi, E., Mancini, M., Nanni, M., Careddu, A., Fazi, F., Padula, F., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2726 · Cited by 123 · cited 3×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
BackgroundKnipp, S., Hildebrand, B., Kündgen, A., Giagounidis, A., Kobbe, G., Haas, R., Aul, C., Gattermann, N., & Germing, U. (2007) · Cancer · doi:10.1002/cncr.22779 · Cited by 113
Self-citationAzacytidine causes complex DNA methylation responses in myeloid leukemia
Stresemann, C., Bokelmann, I., Mahlknecht, U., & Lyko, F. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0411 · Cited by 109 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Wijermans, P., Lübbert, M., Verhoef, G. E. G., Klimek, V. M., & Bosly, A. (2005) · Annals of Hematology · doi:10.1007/s00277-005-0012-1 · Cited by 104 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Self-citationBello, C. M., Yu, D., Komrokji, R. S., Zhu, W., Wetzstein, G. A., List, A. F., & Lancet, J. E. (2010) · Cancer · doi:10.1002/cncr.25598 · Cited by 82 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Sekeres, M. A., Gundacker, H., Lancet, J., Advani, A., Petersdorf, S., Liesveld, J., Mulford, D., Norwood, T., Willman, C. L., Appelbaum, F. R., et al. (2011) · Blood · doi:10.1182/blood-2011-02-337303 · Cited by 80 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Trus, M., Yang, L., Suárez, F., Bordeleau, L. J., Jurišica, I., & Minden, M. D. (2005) · Leukemia · doi:10.1038/sj.leu.2403773 · Cited by 80
Niitsu, N., Hayashi, Y., Sugita, K., & Honma, Y. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02523.x · Cited by 69
Superiority of prolonged low‐dose azanucleoside administration?
Rüter, B. H., Wijermans, P., & Lübbert, M. (2006) · Cancer · doi:10.1002/cncr.21796 · Cited by 63 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Self-citationChun, K., Hagemeijer, A., Iqbal, M. A., & Slovak, M. L. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.07.006 · Cited by 56 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Self-citationCorsetti, M. T., Salvi, F., Perticone, S., Baraldi, A., Paoli, L. D., Gatto, S., Pietrasanta, D., Pini, M., Primon, V., Zallio, F., et al. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.02.021 · Cited by 53 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Rüter, B. H., Wijermans, P., Claus, R., Kunzmann, R., & Lübbert, M. (2007) · Blood · doi:10.1182/blood-2007-03-080630 · Cited by 53
Self-citation“I Am Older, Not Elderly,” Said the Patient With Acute Myeloid Leukemia
Schiffer, C. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8616 · Cited by 37 · cited 1×
“8) duration of MDS; months, median (range) 8 (1-101) missing 14”
Momparler, R. L., Doré, B. T., & Momparler, L. F. (1990) · Cancer Letters · doi:10.1016/0304-3835(90)90086-d · Cited by 37 · cited 2×
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Hassan, S., & Smith, M. (2014) · Hematology · doi:10.1179/1024533214z.000000000312 · Cited by 10
Cited by
Acute myeloid leukaemia in adults
Ferrara, F., & Schiffer, C. A. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61727-9 · Cited by 563
Deschler, B., Ihorst, G., Platzbecker, U., Germing, U., Marz, E., de Figuerido, M., Fritzsche, K., Haas, P., Salih, H. R., Giagounidis, A., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.067892 · Cited by 214
“This is an open-access paper. doi:10.3324/haematol.2012.067892 The online version of this article has a Supplementary Appendix.”
MethodInfluentialSelf-citationEpigenetic modifications: Key players in cancer heterogeneity and drug resistance
Sadida, H. Q., Abdulla, A., Marzooqi, S. A., Hashem, S., Macha, M. A., Akil, A. S. A.-S., & Bhat, A. A. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101821 · Cited by 151
Current status and new treatment approaches in TP53 mutated AML
Hunter, A. M., & Sallman, D. A. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.004 · Cited by 102
Metadata
- Authors
- Lubbert, M., Ruter, B. H., Claus, R., Schmoor, C., Schmid, M., Germing, U., Kuendgen, A., Rethwisch, V., Ganser, A., Platzbecker, U., Galm, O., Brugger, W., Heil, G., Hackanson, B., Deschler, B., Dohner, K., Hagemeijer, A., Wijermans, P. W., & Dohner, H.
- Venue
- Haematologica
- Published
- 2011-11-04
- Volume
- 97
- Issue
- 3
- Pages
- 393-401
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W2149058047
- Cited by
- 230
- References
- 46
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.